Home › Research › Risk factors
The effect of direct cognitive assessment in the Medicare annual wellness visit on dementia diagnosis rates
Kimberly E. Lind, Kerry L. Hildreth, Richard C. Lindrooth, Elaine H. Morrato, Lori A. Crane, Marcelo Coca Perraillon. Health Services Research, 2021-01-22
Topic: Risk, prevention and care in population studies
Plain-language summary
Annual Wellness Visit utilization was associated with an increased probability of new dementia diagnosis with effects varying by racial group (categorized as white, black, Hispanic/Latino, or Asian based on Social Security Administration data). Hazard ratios (95% confidence intervals) for new dementia diagnosis within 6 months of AWV utilization were as follows: 2.34 (2.13, 2.58) white, 2.22 (1.71, 2.89) black, 4.82 (2.94, 7.89) Asian, and 6.14 (3.70, 10.19) Hispanic (P < .001 for each). Our findings show that estimates that do not control for selection underestimate the effect of AWV on new diagnoses. Dementia diagnosis rates increased with AWV implementation with heterogenous effects by race and ethnicity. Current recommendations by the United States Preventive Services Task Force state that the evidence is insufficient to recommend for or against screening for cognitive impairment in older adults.
What this study adds
Evidence grade: Low
This study found that attending a Medicare Annual Wellness Visit was associated with an increased probability of receiving a new dementia diagnosis, with effects varying by racial group. It is about diagnosis rates, not about treating, curing, or preventing Alzheimer's disease.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Lind, K. E., Hildreth, K. L., Lindrooth, R. C., Morrato, E. H., Crane, L. A., & Perraillon, M. C. (2021). The effect of direct cognitive assessment in the Medicare annual wellness visit on dementia diagnosis rates. Health Services Research. https://doi.org/10.1111/1475-6773.13627
Vancouver
Lind KE, Hildreth KL, Lindrooth RC, Morrato EH, Crane LA, Perraillon MC. The effect of direct cognitive assessment in the Medicare annual wellness visit on dementia diagnosis rates. Health Services Research. 2021. doi:10.1111/1475-6773.13627. PMID: 33481263.
BibTeX
@article{lind2021-33481263,
author = {Lind, Kimberly E. and Hildreth, Kerry L. and Lindrooth, Richard C. and Morrato, Elaine H. and Crane, Lori A. and Perraillon, Marcelo Coca},
title = {{The effect of direct cognitive assessment in the Medicare annual wellness visit on dementia diagnosis rates}},
journal = {Health Services Research},
year = {2021},
doi = {10.1111/1475-6773.13627},
pmid = {33481263},
url = {https://doi.org/10.1111/1475-6773.13627}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Annual Wellness Visit utilization was associated with an increased probability of new dementia diagnosis with effects varying by racial group (categorized as white, black, Hispanic/Latino, or Asian based on Social Security Administration data).
- Hazard ratios (95% confidence intervals) for new dementia diagnosis within 6 months of AWV utilization were as follows: 2.34 (2.13, 2.58) white, 2.22 (1.71, 2.89) black, 4.82 (2.94, 7.89) Asian, and 6.14 (3.70, 10.19) Hispanic (P < .001 for each).
- Our findings show that estimates that do not control for selection underestimate the effect of AWV on new diagnoses.
- Dementia diagnosis rates increased with AWV implementation with heterogenous effects by race and ethnicity.
- Current recommendations by the United States Preventive Services Task Force state that the evidence is insufficient to recommend for or against screening for cognitive impairment in older adults.
Why it matters
This study found that attending a Medicare Annual Wellness Visit was associated with an increased probability of receiving a new dementia diagnosis, with effects varying by racial group. It is about diagnosis rates, not about treating, curing, or preventing Alzheimer's disease.
New to this subject? Start with our plain-English guide: Risk factors, ranked →
Study details
- Evidence strengthLow
How this study scored 43/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Health Services Research) |
| Journal's citation record | 2 / 4 | Health Services Research: journal h-index 166 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 3 / 5 | 2021 — within 6 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 3 / 7 | Cited 38 times (OpenAlex, 2026-10-10) |
| Citations per year | 2 / 5 | 5.4 citations a year over 7 year(s) since 2021 |
| Impact for its field and year | 3 / 6 | Cited 3.8× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 2 / 6 | Cited by 4 other studies in this library |
| Still being cited | 2 / 4 | Cited 26 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Marcelo Coca Perraillon: h-index 22 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | University of Arizona: institution h-index 1,336 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 3 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 33481263) |
| Free to read | 2 / 2 | Free to read |
| Total | 43 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
4 studies in the alzhub library list this one in their references.
Related studies in Risk factors from nearby years
Also tagged “prevalence”
1,224 studies in the library carry the topic tag “prevalence”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,224 tagged studies.